Day 2 - Morning

Group 4A: HER2+ Breast Cancer; Antibody-drug Conjugates; Brain Metastasis; Clinical Trials; Novel Targets & Therapies Sold Out

Group 4B: HER2-low & HER2-zero Breast Cancer; Brain Metastasis; Underserved Populations

Group 4C: HR+ Breast Cancer; Biomarkers; Clinical Trials; Targeted Therapies Sold Out

Group 4D: Inflammatory & Triple Negative Breast Cancer; Biomarkers; Clinical Trials; Immunotherapy

Group 4E: Pan-Cancers; Symptoms & Survivorship

Group 4F: HER2+ & Triple Negative Breast Cancer; Brain Metastasis; Clinical Trials; Immunotherapy Last Few Tickets

Group 4G: HR+ Breast Cancer; Hormone Therapies; Real-World Data/Outcomes; Targeted Therapies Last Few Tickets